Researchers have carried out clinical trials to test a mutation-specific vaccine against malignant brain tumors. The vaccine has been found to be safe and effective in triggering the desired immune response in the brain cancer tumors.
When injected with the new mRNA vaccine, mice with multiple sclerosis-like symptoms developed less severe symptoms than would normally occur.
A newly developed experimental vaccine can diminish the fatal respiratory effects of carfentanil and fentanyl in rodent models.
By adding a molecule that disrupts certain pathways in cells, researchers have discovered a new way to limit inflammation from adjuvants in vaccinations.
Using computational methods, researchers created artificial proteins that triggered immune responses and produced infection specific antibodies. The findings indicate it will be possible to design vaccines that contain artificial antibodies, expediting the process of vaccine development.
Researchers report they have identified a vaccine candidate for COVID-19 and are working towards phase one clinical testing. A chimpanzee adenovirus vaccine vector was chosen as the most suitable vaccine technology for SARS-CoV-2 as it can generate a stronger immune response in one dose and is not a replicating virus.
Researchers are making progress in developing potential vaccines for coronavirus infections. While a vaccine for COVID-19 might be over a year away from market, researchers are looking ahead to attempt to prevent future outbreaks.
Clinical trials for a preventative treatment for dementia was successful in mouse models. Researchers say human trials will begin in two years.
A newly developed vaccine for meningitis and other bloodstream infections caused by the meningococcal group B bacteria will allow for the immunization of younger children. The new vaccine also addresses several limitations of the current meningitis vaccine.
Researchers have engineered a vaccine using virus-like particles that target Tau tangles in mouse models of Alzheimer's disease. Following the administration of the vaccine, the mice developed antibodies that cleared tau proteins, with the response lasting for a month. The mice also showed improvements in memory based tests and had less brain shrinkage than their peers who did not receive the vaccine. This suggests the vaccine prevented apoptosis. Researchers hope to move the vaccine to human clinical trials in the future.
From anti-vaccine rhetoric to the over-prescription of antibiotics, researchers suggest we should try to work together to improve public health, rather than socially shun those who ignore scientific evidence.
Researchers report one method to help combat anti-vaccine information and reduce vaccine hesitancy is to introduce those with negative views about immunizations to someone who has suffered a vaccine-preventable disease. The study reports 70% of students who were exposed to someone with a vaccine-preventable disease moved from vaccine hesitancy to pro-vaccine. Overall, 75% of those who were anti-vaccine increased their vaccine attitude scores, with 50% moving to a pro-vaccine stance.
